THX-TS01

Drug Profile

THX-TS01

Alternative Names: THX RS01; THX TS01

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Therapix Biosciences
  • Class Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome

Most Recent Events

  • 01 Feb 2017 Phase-III clinical trials in Gilles de la Tourette's syndrome in USA (unspecified route) (NCT03066193)
  • 23 Dec 2016 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (unspecified route)
  • 01 Jul 2016 Therapix Biosciences and Yale University files an iIND application with the FDA in USA for Tourette's syndrome (Therapix Biosciences Quarterly Report, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top